MiRNA set dysregulation in breast cancer cells can contribute to both primary and acquired resistance to immune checkpoint blockade

      Background: One of the main immune escape mechanisms used by tumors is the exploitation of immune checkpoints – receptors on surface of immune cells, which, after binding their ligands, can suppress immune response. Consequently, immune checkpoint blockade is considered as promising approach for cancer treatment. However, currently available anti-CTLA-4 and anti-PD-1/anti-PD-L1 drugs have shown limited efficiency against many common cancer types (e.g. breast cancer). This research aims to identify in what way the shifts in miRNA expression pattern can contribute to the resistance of breast cancer cells to the immune checkpoint inhibitors and to the weakening of their efficiency during treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect